WEBINAR VIDEO | What do the CJEU’s decisions on parallel trade of medicines mean for your company?
At this additional Christmas edition, the IP specialists in our Life Sciences team discuss the CJEU’s latest decisions on the parallel trade of medicines, and what these decisions mean in practice for your company.
On 17 November 2022, the CJEU delivered essentially two decisions on the parallel trade of medicines. The first concerned the rebranding of generic medicines to the branded reference medicine (in joined cases C-253/20 and C-254/20), and about which we published a blog on 24 November 2022. The second addressed the impact of anti-tampering devices on the possibility, and objective necessity, to rebox (in C-224/20 and C-147/20), and about which we published a blog on 2 December 2022.
Contact
Recommended articles
Screws loose? The CJEU weighs in on a trade mark parody gone political
CJEU’s judgment of 8 September 2026 in Case C-298/23, Inter IKEA Systems BV v Algemeen Vlaams Belang VZW (Reference for a preliminary ruling from the Nederlandstalige Ondernemingsrechtbank Brussel – Brussels Dutch-speaking Business Court, Belgium). 1. Summary of the facts On 14 November 2022, the Belgian far-right political party Vlaams Belang publicly presented, at a press […]
Read on
Belgian Pharma Law Summer Blog Series (Part 3): the recently passed ‘Bill containing various provisions on health’
In our Belgian Pharma Law Summer Blog Series, we examine recent developments in Belgian pharmaceutical law. Whether you are looking for an informative summer read or a concise overview of the latest legal developments to catch up on after the holidays, our series has you covered. Our third and final part examines the ‘Bill containing […]
Read on
Belgian Pharma Law Summer Blog Series (Part 2): the new ‘Article 10 guidance’ on pharmaceutical promotion
In our Belgian Pharma Law Summer Blog Series, we examine recent developments in Belgian pharmaceutical law. Whether you are looking for an informative summer read or a concise overview of the latest legal developments to catch up on after the holidays, our series has you covered. Part 2 focuses on the new guidance on the […]
Read on